ストックスクリーナーアプリを入手
3.65
2.41%
-0.09
前日終値:
$3.74
開ける：
$3.76
24時間の取引高:
8.47M
Relative Volume:
1.59
時価総額：
$1.03B
収益：
$194.75M
当期純損益:
$-51.26M
株価収益率:
-13.04
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-0.82%
1か月 パフォーマンス:
+25.00%
6か月 パフォーマンス:
+87.18%
1年 パフォーマンス:
+268.99%
1日の値動き範囲:
$3.60
$3.76
1週間の範囲:
$3.48
$3.87
52週間の値動き範囲:
$0.91
$4.0758
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.65 | 1.03B | 194.75M | -51.26M | -23.38M | -0.28 |
|
RGC
Regencell Bioscience Holdings Ltd
|
17.40 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
156.17 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.38 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-28 | 開始されました | Leerink Partners | Outperform |
| 2025-04-01 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 再開されました | BTIG Research | Buy |
| 2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-31 | ダウングレード | Needham | Buy → Hold |
| 2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 繰り返されました | Needham | Buy |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-02 | 開始されました | JP Morgan | Overweight |
| 2019-03-20 | 開始されました | Citigroup | Neutral |
| 2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 繰り返されました | Needham | Buy |
| 2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-12-19 | 開始されました | Piper Jaffray | Overweight |
| 2017-12-07 | 開始されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | Needham | Buy |
| 2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-15 | 開始されました | Aegis Capital | Buy |
| 2016-09-29 | 開始されました | Brean Capital | Buy |
| 2016-03-16 | 繰り返されました | Needham | Buy |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st
AVEROA - The Pharma Letter
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Akebia Therapeutics expands stock incentive plan - Investing.com Australia
Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa
Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks
Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha
Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN
Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa
Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha
Akebia reports mixed results for anemia drug in global study - Investing.com Australia
Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus
Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus
Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq
Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance
H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com
Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus
Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa
Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire
Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan
Akebia’s patent for Anemia therapy gets fresh blood from Court - BananaIP
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire
Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India
Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada
Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia
Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
Akebia Therapeutics Inc (AKBA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Malabre Richard C | SVP, Chief Accounting Officer |
Jun 09 '25 |
Sale |
4.01 |
15,000 |
60,150 |
266,914 |
| Malabre Richard C | SVP, Chief Accounting Officer |
Jun 04 '25 |
Sale |
3.53 |
13,334 |
47,069 |
266,914 |
| Butler John P. | CEO and President |
Mar 03 '25 |
Sale |
1.83 |
46,409 |
84,928 |
2,557,921 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Mar 03 '25 |
Sale |
1.83 |
7,144 |
13,074 |
809,090 |
0.07%
0.06%
大文字化:
|
ボリューム (24 時間):